Background {#Sec1}
==========

Maternal metabolic adaptations are required during pregnancy to meet the nutrient demands of the growing placenta and fetus \[[@CR1]\]. These changes include shifts into anabolic metabolism during the first and second trimesters \[[@CR2]\]. This allows for fat accumulation in the mother, to be used as an energy source for maternal tissues during the third trimester, when a switch to catabolic metabolism takes place to ensure an enhanced nutrient supply to the growing fetus \[[@CR2]-[@CR6]\]. These adaptations to meet fetal requirements for growth encompass large changes in maternal glucose, carbohydrate, amino acid, lipid and fatty acid metabolism \[[@CR2],[@CR7]\]. An inability of the maternal system to make these adjustments and ensure appropriate nutrient supply for both maternal and fetal tissues may underpin some of the obstetric complications associated with poor fetal growth and placental insufficiency \[[@CR8]\].

While creatine is thought to be an essential metabolite for the growing fetus \[[@CR9],[@CR10]\], whether maternal creatine metabolism is altered in pregnancy has received little attention. Creatine and its intracellular phosphorylated derivative, phosphocreatine, have an important role in cellular ATP turnover \[[@CR11]\]. Creatine is readily obtained from a diet of animal products and is also synthesised by the body through the production of guanidinoacetate (GAA), catalysed by the enzyme arginine:glycine aminotransferase (AGAT) predominately in the kidney, followed by the methylation of GAA, mainly in the liver, to produce creatine \[[@CR12]\]. Once synthesised or absorbed creatine is moved into tissues by the creatine transporter-1 protein (CrT1) \[[@CR13]\] where \~75% is phosphorylated and used as a source of phosphate for the regeneration of ATP \[[@CR14]\].

Creatine has been shown to cross the human placenta \[[@CR10]\]. However the source of this creatine is not known. In rats, AGAT, GAMT, and CrT1 are expressed in most tissues of the embryo from early in gestation \[[@CR15]\]. Yet studies in the spiny mouse, a precocial species that has a number of reproductive similarities to human pregnancy in terms of *in utero* organ development \[[@CR16]-[@CR18]\] and endocrine function \[[@CR19]\], identified that creatine was accrued during gestation by the placenta and fetal tissues, but that the fetus had limited capacity for creatine synthesis until 0.9 of gestation \[[@CR20]\]. This suggests that creatine supply to the placenta and fetus in mammals that give birth to well-developed young is maternal in origin for much of gestation. This raises questions about how the maternal system provides for the proposed increase in need for creatine during pregnancy. Thus, the objective of this study was to describe maternal creatine homeostasis during gestation in the spiny mouse.

Methods {#Sec2}
=======

Spiny mice {#Sec3}
----------

All experiments were approved in advance by Monash University Animal Ethics Committee and conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. Spiny mice (*Acomys cahirinus*) were bred and housed as previously described \[[@CR21]\]. Pregnant and virgin female spiny mice were used to conduct this study. Control females and near-term pregnant dams (37 days gestation \[dGA\]; term is 39 days) were killed by cervical dislocation and the brain, liver, kidney, heart and gastrocnemius muscle were excised, weighed, snap frozen and stored at −80°C.

Body composition {#Sec4}
----------------

After post mortem whole frozen bodies (non-pregnant n = 6; pregnant n = 6 (excluding the uterus and fetal tissues for the pregnant cohort)) were subjected to Dual-energy X-ray absorptiometry (DEXA; Lunar PIXImus, GE Medical Systems, Wisconsin), for assessment of lean tissue mass, bone mineral density (BMD) and tissue fat mass \[[@CR22]\].

Urine collection {#Sec5}
----------------

Non-pregnant females (n = 6), and pregnant dams (n = 6) at 23dGA and 35dGA were placed in a metabolic cage apparatus (Monash Scientific Glass, Dandenong, Victoria) for 12 hours (h) during the dark cycle (19:00--07:00) to facilitate the collection of urine for measurement of creatine. Food and water intake were also measured during this time.

Plasma collection {#Sec6}
-----------------

Non-pregnant female spiny mice (n = 6) and pregnant dams (23dGA, 35dGA and term) (n = 6-9/time-point) were anesthetised and whole blood was collected by cardiac puncture, before the spiny mice were killed by cervical dislocation. Whole blood was centrifuged at 4°C and 3000 *g* for 10 mins. Plasma was then frozen and stored at −20°C.

Measuring creatine {#Sec7}
------------------

Tissues (brain, liver, kidney, heart, gastrocnemius muscle; 3--4 mg) were freeze-dried, powdered and extracted with 0.5 mol/L perchloric acid and 1 mmol/L ethylenediaminetetraacetic acid (EDTA) before being neutralized with 2.1 mol/L potassium hydrogen carbonate. Plasma and urine were extracted with 1.5 M perchloric acid (50 μl acid/100 μl sample) before being neutralized with 2.1 mol/L potassium hydrogen carbonate. Extracted samples were used to determine total creatine content by enzymatic analysis of creatine and phosphocreatine with fluorometric detection as previously described \[[@CR9],[@CR23],[@CR24]\]. Wet:dry tissue weight ratios were used to calculate estimated total creatine content per organ for kidney, liver, brain and heart samples. The calculated urinary excretion rate of creatine was based on the volume of urine collected over the 12 h period.

Gene expression {#Sec8}
---------------

Real-time quantitative polymerase chain reaction (RT-qPCR) was used to determine the mRNA expression of the creatine transporter-1 (CrT1) *(SLC6A8)* \[GenBank: NM\_ 133987.2\] and creatine synthesising enzymes AGAT *(GATM)* \[GenBank: NM_025961\] and *GAMT* \[GenBank: NM_010255.3\] in the brain, liver, kidney, heart and gastrocnemius muscle as described previously \[[@CR20]\]. Cyclophilin A *(peptidylprolyl isomeraseA; PPIA)* \[GenBank: NM_017101.1\] was used as the housekeeping gene. Primer sequences are shown in Table [1](#Tab1){ref-type="table"}. Total RNA was extracted using RNeasy Kits (Qiagen, Glen Forrest, Australia) and reverse transcribed, according to manufacturer's instructions (Promega, Madison, Wisconsin). RT-qPCR was completed using a Stratagene MX3000p thermal cycler system with SYBR green PCR Mastermix (Applied Biosystems, Carlsband, California). Cycling conditions were: 95°C 10mins; 95°C 15secs, 60°C 1 min ×40 cycles; 95°C 5secs, 60°C 15secs, 95°C 15secs ×40 cycles. Data obtained from qPCR were analysed using the ^ΔΔ^CT method \[[@CR20],[@CR25]\], with results expressed relative to non-pregnant controls.Table 1**Primer Sequences**GeneAccession number (GenBank)Forward prime sequence (5′-3′)Reverse primer sequence (3′-5′)Source**CrT1** ***(SLC6A8)***NM_133987.2TCCTGGCACTCATCAACAGATGAAGCCCTCCACACCTAC\[[@CR20]\]**AGAT** ***(GATM)***NM_025961TCACGCTTCTTTGAGTACCGTCAGTCGTCACGAACTTTCC\[[@CR20]\]**GAMT**NM_010255.3TGGCACACTCACCAGTTCAAAGGCATAGTAGCGGCAGTC\[[@CR20]\]**Cyclophilin A** ***(PPIA)***NM_017101.1CTGATGGCGAGCCCTTGCTGCTGTCTTTGGAACTTTGTC\[[@CR20]\]Oligonucleotide primer sequences used for the amplification and RT-qPCR analysis of creatine synthesizing enzymes and the creatine transporter.

Protein expression {#Sec9}
------------------

Frozen tissues (\~10 mg) were solubilised in 12.5% Tris--HCl (pH 6.8), 10% Glycerol, 20% of 0.1 SDS/ dH~2~O and 10% protease inhibitor in dH~2~O overnight. Samples were centrifuged and protein concentration of supernatants determined by the bicinchoninic acid assay, following manufacturers instructions (BCA Protein Assay Kit\#23225, Thermo Scientific, Scoresby, Australia). Aliquots of samples at a final protein concentration of 40 μg were separated by SDS-PAGE using Novex NuPAGE precast Tris-base 4-12% gels according to manufacturer's instructions (Life Technologies, Mulgrave, Victoria). To account for inter-gel variability, samples from all groups were included on each gel and protein samples extracted from an adult spiny mouse kidney (AGAT) and liver (GAMT) used as an internal control across all gels. Protein was transferred to PVDF membranes, blocked for 1-h in 5% skim milk buffer (SMB) and incubated overnight in 1:70 anti-AGAT (Biorbyt, GATM antibody, orb28345, Cambridgeshire, United Kingdom, band size 47 kDa) or 1:250 anti-GAMT in 2.5% SMB (an affinity purified mouse monoclonal antibody, made through injection of the antigenic peptide N-terminal aa 125--145, band size 26 kDa; Monash Antibody Technologies Facility, Melbourne, Australia). Membranes were then incubated for 1-h with fluorescent secondary antibodies (Anti-Mouse IgG(H + L) Daylight™ 680 Conjugate or Anti-Rabbit IgG(H + L) Daylight™ 800 Conjugate; Cell Signalling Technologies®, Danvers, USA), before being scanned using the LiCOR® OdysseyCLx® Imaging System (Millennium Science, Mulgrave, Victoria). Membranes were then re-probed as above for GAPDH (G8795, Sigma-Aldrich, Castle Hill, NSW, band size 37 kDa), which was used as the loading control. Protein expression was determined by densitometry using Image Studio Lite™ software. Results are presented relative to non-pregnant controls. *Note:* due to the lack of a specific CrT1 antibody we were unable to perform western blots for this protein \[[@CR26],[@CR27]\].

Data analysis and statistics {#Sec10}
----------------------------

Data are presented as means ± SEM. A Students t-Test for two independent samples was used to compare body composition, organ weights, tissue creatine content, and expression of creatine synthesising enzymes between pregnant and non-pregnant animals. A One-Way ANOVA with Bonferroni's correction for multiple comparisons was used to assess plasma creatine concentration and urinary creatine excretion, by comparing the difference at two time-points during pregnancy to the non-pregnant controls. Prism 6 Graphpad software™ was used to perform statistical comparisons.

Results {#Sec11}
=======

Body composition and organ weights {#Sec12}
----------------------------------

At term the bone mineral density of pregnant spiny mice was significantly lower (14%) compared to non-pregnant females (Table [2](#Tab2){ref-type="table"}; P \< 0.05). Maternal lean tissue mass was increased with pregnancy by 16% (Table [2](#Tab2){ref-type="table"}; P \< 0.01), with no evident change in tissue fat mass (Table [2](#Tab2){ref-type="table"}). Kidney mass was 26% greater at term in the pregnant spiny mouse compared to non-pregnant controls (Table [3](#Tab3){ref-type="table"}; P \< 0.01). Liver mass of pregnant spiny mice was also greater than controls by 29% (Table [3](#Tab3){ref-type="table"}; P \< 0.01) and hypertrophy of the heart in pregnant spiny mice was evident with a 12% increase in mass (Table [3](#Tab3){ref-type="table"}; P \< 0.05). No change in brain weight was observed between non-pregnant and pregnant spiny mice (Table [3](#Tab3){ref-type="table"}).Table 2**Whole Body Dual X-ray Absorptiometry**Dual X-ray AbsorptiometryNon-pregnantPregnantStatistics**BMD (g/cm** ^**2**^ **)**0.066 ± 0.0010.057 ± 0.001**\<0.05Tissue- Lean Mass (g)**24.9 ± 0.629.6 ± 1.3**\<0.01Tissue- Fat Mass (g)**8.7 ± 0.69.0 ± 0.6**NS**The effect of pregnancy on bone mineral denisty (BMD; g/cm^2^), tissue lean mass (g) and tissue fat mass (g). Values are means ± SEM; n = 6-8/group. Statistical analysis Students t-Test. Significance P ≤ 0.05.Table 3**Organ Weights**OrgansNon-pregnantPregnantStatistics**Kidney (mg)**225.5 ± 11.0305.1 ± 8.7**\<0.01Liver (g)**0.899 ± 0.0011.26 ± 0.05**\<0.01Heart (mg)**119.5 ± 9.1134.7 ± 4.1**\<0.05Brain (mg)**823.8 ± 12.9864.6 ± 10.7**NS**The weight (mg or g) of non-pregnant and term pregnant spiny mouse kidney, liver**,** heart and brain. Values are means ± SEM; n = 6-8/group for organ weights. Statistical analysis Students t-Test. Significance P ≤ 0.05.

Plasma and urinary creatine concentration {#Sec13}
-----------------------------------------

Plasma creatine levels were significantly lower in pregnant compared to non-pregnant spiny mice (Figure [1](#Fig1){ref-type="fig"}A; P \< 0.001) with the greater part of this decrease having occurred by 23dGA (0.58 gestation). Urinary creatine excretion was significantly lower in pregnant spiny mice than non-pregnant controls (Figure [1](#Fig1){ref-type="fig"}B; P \< 0.05), with creatine excretion decreasing significantly between 23dGA and 35dGA (P \< 0.01). No difference in food intake, from which dietary creatine consumption was calculated, was noted between non-pregnant and pregnant spiny mice at 23dGA or 35dGA (data not shown).Figure 1Maternal Plasma Creatine Concentration and Urinary Creatine Concentration from Mid to Late Gestation. **(A)** Plasma creatine concentration (μmol/L) of non-pregnant controls and pregnant spiny mice at 23d GA, 35d GA and term. **(B)** Urinary creatine excretion (mgCr/12 h) in non-pregnant and pregnant spiny mice at 23d GA and 35d GA. Values are means ± SEM; n = 6-8/group. Statistical analysis One-Way ANOVA with Bonferroni Multiple Comparisons. Significance P ≤ 0.05; \*P \<0.05, \*\*P \< 0.01, \*\*\*P \< 0.001.

AGAT and GAMT expression {#Sec14}
------------------------

Renal expression of AGAT, measured as mRNA and protein, were both significantly increased during pregnancy (Figure [2](#Fig2){ref-type="fig"}A & B; P \< 0.01, P \< 0.05, respectively). In contrast to the kidney, AGAT mRNA expression in the heart was lower in pregnant dams compared to non-pregnant controls (Table [4](#Tab4){ref-type="table"}; P \< 0.01), and there was a strong trend for heart AGAT protein expression to be lower with pregnancy (P = 0.054). AGAT mRNA expression was also significantly lower in the brain (P \< 0.01) and gastrocnemius muscle (P \< 0.01) of term pregnant dams compared to their non-pregnant counterparts, but with no significant change in the amount of AGAT protein present in these tissues (Table [4](#Tab4){ref-type="table"}).Figure 2Maternal AGAT and GAMT Expression in the Kidney and Liver. Maternal kidney AGAT mRNA **(A)** and protein **(B)** expression significantly increased at term, compared to non-pregnant controls. No change in liver GAMT mRNA **(C)** was observed, however GAMT protein was decreased at term **(D)**. Data are expressed relative to the house keeping gene/protein. Values are means ± SEM; n = 6-8/group. Statistical analysis Students t-Test. Significance P \< 0.05; \*P \<0.05.Table 4**Tissue AGAT and GAMT Expression**BrainHeartGastrocnemius muscleNon-pregnantPregnantStatsNon-pregnantPregnantStatsNon-pregnantPregnantStats**AGAT mRNA**1.00 ± 0.060.48 ± 0.10**\<0.01**1.00 ± 0.250.20 ± 0.02**\<0.01**1.00 ± 0.110.40 ± 0.03**\<0.01AGAT Protein**1.00 ± 0.120.73 ± 0.18**NS**1.00 ± 0.260.46 ± 0.07**0.054**1.00 ± 0.451.23 ± 0.65**NSGAMT mRNA**1.00 ± 0.150.23 ± 0.05**\<0.001**1.00 ± 0.290.68 ± 0.05**NS**1.00 ± 0.130.78 ± 0.10**NSGAMT Protein**1.00 ± 0.460.20 ± 0.07**0.05**1.00 ± 0.372.27 ± 0.35**\<0.05**1.00 ± 0.420.77 ± 0.28**NS**mRNA and protein expression of AGAT and GAMT in the brain, heart and skeletal muscle of non-pregnant and pregnant spiny mice at term. Data are expressed relative to the house keeping gene/protein. Values are means ± SEM; n = 6/group. Statistical analysis Students t-Test. Significance P ≤ 0.05.

Analysis of hepatic GAMT identified no difference in mRNA expression between the pregnant and non-pregnant groups (Figure [2](#Fig2){ref-type="fig"}C), however GAMT protein expression was significantly decreased in the liver of term pregnant spiny mice compared to non-pregnant controls (Figure [2](#Fig2){ref-type="fig"}D; P \< 0.01). GAMT mRNA (P \< 0.001) and protein (P \< 0.05) were both lower in the maternal brain at term compared to the brain in non-pregnant spiny mice (Table [4](#Tab4){ref-type="table"}). Pregnancy was also associated with an increase in GAMT protein expression in maternal cardiac homogenates at term (Table [4](#Tab4){ref-type="table"}; P \< 0.01).

Expression of CrT1 and tissue creatine content {#Sec15}
----------------------------------------------

Cardiac CrT1 mRNA expression was significantly higher in pregnant dams compared to non-pregnant controls (Figure [3](#Fig3){ref-type="fig"}C; P \< 0.05), as was the creatine content of the heart (Table [5](#Tab5){ref-type="table"}; P \< 0.05). While pregnancy had no effect on creatine content in the liver (Table [5](#Tab5){ref-type="table"}), hepatic CrT1 mRNA was significantly lower in pregnant dams compared to non-pregnant controls (Figure [3](#Fig3){ref-type="fig"}A; P \< 0.001). The creatine content in the brain was also not different between pregnant and non-pregnant females (Table [5](#Tab5){ref-type="table"}), although brain CrT1 mRNA expression was significantly decreased in pregnant dams (Figure [3](#Fig3){ref-type="fig"}B; P \< 0.01). Up-regulation of CrT1 mRNA in the gastrocnemius muscle was also observed with pregnancy (Figure [3](#Fig3){ref-type="fig"}D; P \< 0.05), but creatine content in the gastrocnemius muscle was not different between pregnant and non-pregnant spiny mice (Table [5](#Tab5){ref-type="table"}). The renal expression of CrT1 mRNA was not different between pregnant and non-pregnant spiny mice, however a significant increase in kidney creatine content was detected with pregnancy (Table [5](#Tab5){ref-type="table"}; P \< 0.001).Figure 3Maternal Creatine Transporter Expression. Creatine transporter 1 (CrT1) mRNA expression was reduced in the liver **(A)** and brain **(B)** of pregnant spiny mice at term. An increase in CrT1 mRNA expression, relative to non-pregnant controls, was observed in the heart **(C)** and gastrocnemius muscle **(D)** of term pregnant spiny mice. Data are expressed relative to the house keeping gene/protein. Values are means ± SEM; n = 6-8/group. Statistical analysis Students t-Test. Significance P ≤ 0.05; \*P \<0.01.Table 5**Tissue Creatine Content**Tissue creatine contentNon-pregnantPregnantStatistics***Estimated Total Creatine per Organ (nmol)*Kidney**520.9 ± 48.36912.61 ± 48.36\<0.001**Liver**2432.4 ± 548.32554.1 ± 557.8NS**Brain**14443.0 ± 399.912933.7 ± 1109.5NS**Heart**1540.4 ± 107.71899.9 ± 72.36\<0.05***Total Creatine (mmol/kg Dry Weight)*Gastrocnemius Muscle**136.1 ± 9.4124.1 ± 3.0NSEstimated total creatine content per organ (nmol). Data calculated from total creatine content, wet/dry weight ratio and wet mass per organ, except for the gastrocnemius muscle (mmol/kg dry mass). Values are means ± SEM; n = 6/group. Statistical analysis Students t-Test. Significance P ≤ 0.05.

Discussion {#Sec16}
==========

To our knowledge this is the first study to document changes in maternal creatine metabolism during pregnancy. As creatine delivery to the placenta and fetus appears to be of maternal origin in precocial species, changes to maternal creatine homeostasis maybe a necessary adjustment of maternal metabolism to pregnancy in much the same way that alterations to glucose, amino acid, carbohydrate, lipid and fatty acid metabolism are required to support growing maternal tissues, the placenta and fetus \[[@CR2]\].

Changes to creatine demand during pregnancy development {#Sec17}
-------------------------------------------------------

Maternal plasma creatine concentrations and urinary creatine excretion were both significantly decreased in pregnancy. The rate of entry and removal of creatine into the plasma should be considered when interpreting these findings. Typically, entry of creatine into the maternal plasma would involve its absorption across the gut following ingestion of dietary creatine, and/or the release of creatine into the circulation from organs involved in *de novo* synthesis, mainly the liver \[[@CR11]\]. Removal of circulating creatine may occur during pregnancy by the active transport of creatine into maternal tissues, the spontaneous (non-enzymatic) conversion of creatine to creatinine, excretion of creatine in the urine, or the transfer of creatine across the placenta \[[@CR9],[@CR10],[@CR28],[@CR29]\].

The decreasing rate of urinary creatine excretion from mid to late gestation reported in the spiny mouse limits the probability that the decline in plasma creatine concentration observed in this study is the consequence of increased creatine loss through the kidney. However, the decreased renal excretion of creatine may be directly related to the observed fall in plasma (and hence, filtered) creatine. Whilst this study did not measure the activity of the creatine transporter in the kidney, no change in renal CrT1 gene expression was observed and therefore creatine uptake from glomerular filtrate may not be different between pregnant and non-pregnant spiny mice. Expression of monocarboxylate 12 (MCT12), a transport protein recently identified in kidney tubules and shown to perform facilitated diffusion of creatine was also not assessed in this study, but may play a role in the urinary creatine recovery observed with pregnancy in the spiny mouse \[[@CR30]\].

The increased CrT1 gene expression identified in the heart and gastrocnemius muscle of the pregnant spiny mouse suggests these tissues have an increased capacity for creatine uptake from the circulation during pregnancy. Indeed, the pregnant heart had a significantly higher creatine content at term. These increases may reflect the need for increased phosphate buffering and preservation of ATP associated with the increased cardiac output of 40-50% during pregnancy \[[@CR31],[@CR32]\]. The DEXA results indicate there was an increase in lean tissue mass of the pregnant spiny mouse by term. Previous studies in humans suggest that skeletal muscle contributes to 38-42% of lean tissue mass \[[@CR33],[@CR34]\], and as skeletal muscle is the largest store of creatine in the body, this increased total mass together with the increase of CrT1 mRNA in pregnancy would be expected to result in increased creatine uptake from the maternal plasma into muscle beds. The adaptive value of the increased CrT1 expression may be to ensure that intracellular creatine levels remain at the levels required for normal muscle function. Mediators of increased CrT1 expression may be IGF-1 and triiodothyronine, both of which are up-regulated during pregnancy \[[@CR35],[@CR36]\], and both of which have been shown to increase CrT1 expression and creatine uptake in skeletal myoblast cells by virtue of their effects on the Na^+^ transmembrane potential \[[@CR37]\].

It is also likely that the placenta is an additional 'sink' for maternal plasma creatine, given that the creatine content of placental and fetal tissues increase across gestation \[[@CR10],[@CR20]\]. What initiates changes in placenta CrT1 expression and creatine transfer during human pregnancy remains undetermined. The estrogen-related receptors (ERRα, β and γ) are highly expressed in the human placenta from the 2nd trimester and have been linked with energy metabolism within placental cells \[[@CR38],[@CR39]\]. Recently, studies have described the role of ERRα in the up-regulation of CrT1 mRNA and creatine uptake in a L6 myotubule cell line \[[@CR40]\]. Estrogen-related receptors may therefore be a prime candidate for facilitating creatine uptake into the placenta and maternal tissues during pregnancy. Interestingly, the spiny mouse dietary intake of creatine during pregnancy did not appear to change, suggesting that pregnancy may induce an increase in maternal endogenous creatine synthesis to meet the demand.

Maternal blood volume was not measured in this study, but would be expected to increase, as this is a fundamental, well-characterised adaptation that occurs in both rodent and human pregnancy \[[@CR41],[@CR42]\]. Plasma expansion during pregnancy should thus be determined in the spiny mouse, to elucidate whether increased plasma volume might partially contribute to the decreased plasma creatine levels observed during pregnancy in this study. It is also unknown if creatine absorption across the gut is modified by pregnancy in the spiny mouse or the human. Changes to the gastrointestinal tract have been well characterised in rodent and human pregnancies, including the progesterone-induced decrease in gastrointestinal tract motility \[[@CR43],[@CR44]\]. These adaptations facilitate increased nutrient absorption without an increase in dietary consumption \[[@CR45]\]. As creatine absorption is limited to certain regions of the gut, intestinal transit time is thought to be a factor in creatine uptake under normal physiological conditions \[[@CR46],[@CR47]\]. The slowed movement of substances through the intestine with pregnancy may therefore increase the contact time of creatine with CrT1 sites in the gut and increase intestinal absorption \[[@CR48]\]. The uptake of creatine through the gut during pregnancy should thus be considered in future investigations of maternal creatine homeostasis.

Adaptations to maternal creatine synthesis at term {#Sec18}
--------------------------------------------------

Pregnancy in the spiny mouse was associated with a marked increase in maternal kidney AGAT mRNA and protein expression. As the rate limiting step of creatine synthesis, an increase in renal AGAT expression is considered a key indicator of increased endogenous capacity to synthesise creatine \[[@CR28]\]. Whereas renal AGAT protein expression was greater in the kidney, hepatic GAMT protein expression (per μg of tissue protein) was decreased in pregnant spiny mice. This result suggests that the maximal rate of GAA methylation and thus creatine production in the liver may decrease with pregnancy, although this may be offset by the relatively large (29%) increase in liver size in the pregnant spiny mouse. Further work to establish maternal plasma levels of GAA during pregnancy, and of AGAT and GAMT enzyme activities *in vivo* of the maternal kidney and liver are needed to address these findings. Consideration of subsidiary sites of creatine synthesis such as the pancreas \[[@CR49]\], and the changes to AGAT and GAMT expression observed in the brain, heart and gastrocnemius muscle identified in this study should also be considered when evaluating global maternal creatine production during pregnancy.

Clinical translation {#Sec19}
--------------------

Establishing normative values (mean, range) for maternal plasma creatine and creatine urinary excretion during human pregnancy would be an important extension of these findings in the spiny mouse. Particular consideration should be given to the vegetarian population who obtain little creatine from their diet, and therefore require highly competent function of their renal-hepatic axis to synthesize endogenous creatine. Whether alterations to creatine metabolism have an association with obstetric complications such as poor fetal growth and placental insufficiency should also be considered in human-based studies. Recent literature suggests targeted dietary supplementation can play an essential role in reducing obstetric complications and neonatal mortality \[[@CR50],[@CR51]\]. As a simple dietary intervention, creatine may have the ability to increase the cellular energy reserves of the mother, placenta and fetal organs, and may better outcomes following obstetric complications that lead to cellular energy failure and/or oxidative stress \[[@CR52]\]. Indeed, previous studies conducted in the spiny mouse indicate increasing maternal dietary creatine improves neonatal outcomes following birth asphyxia \[[@CR53]-[@CR55]\].

Conclusions {#Sec20}
===========

Pregnancy in the spiny mouse is associated with increased creatine content in the maternal heart and kidney, together with decreased plasma creatine concentration, decreasing urinary creatine excretion, and shifts in tissue-specific mRNA and protein expression of the enzymes AGAT and GAMT, and gene expression of CrT1. Whether maintenance of maternal creatine homeostasis is critical for fetal growth, and whether similar changes occur in human pregnancy is unknown and should be the focus of future studies.
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